Quick Answer
Quince Therapeutics, Inc. reported Common Stock Shares Outstanding of 44.00 million shares for the year ending 2024.
- Quince Therapeutics, Inc. showed an increase of +2.4% in Common Stock Shares Outstanding from 2023 to 2024.
- This data is from Quince Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: 3.57 million shares | Q2 2019: 26.84 million shares | Q3 2019: 26.84 million shares | Q1 2020: 29.40 million shares | Q2 2020: 29.49 million shares | Q3 2020: 29.49 million shares | Q1 2021: 29.58 million shares | Q2 2021: 29.66 million shares | Q3 2021: 29.87 million shares | Q1 2022: 30.15 million shares | Q2 2022: 35.98 million shares | Q3 2022: 36.13 million shares | Q1 2023: 36.28 million shares | Q2 2023: 36.33 million shares | Q3 2023: 36.34 million shares | Q1 2024: 43.22 million shares | Q2 2024: 43.28 million shares | Q3 2024: 43.28 million shares | Q4 2024: 44.00 million shares | Q1 2025: 44.09 million shares | Q2 2025: 53.62 million shares | Q3 2025: 54.49 million shares.
- Over the full 7 years of available data (2018 to 2024), Quince Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 1,189.5%.
- Historical annual values: Fiscal year 2024: 44.00 million shares | Fiscal year 2023: 42.97 million shares | Fiscal year 2022: 36.14 million shares | Fiscal year 2021: 30.07 million shares | Fiscal year 2020: 29.54 million shares | Fiscal year 2019: 26.87 million shares | Fiscal year 2018: 3.41 million shares.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: